International Journal of Molecular Medical Science, 2024, Vol.14, No.1, 69-79 http://medscipublisher.com/index.php/ijmms 78 Benes L., Brandt D., Brandt E., and Davidson M., 2018, How genomics is personalizing the management of dyslipidemia and cardiovascular disease prevention, Current Cardiology Reports, 20: 1-7. https://doi.org/10.1007/s11886-018-1079-3 PMid:30328514 Becheva M., Kirkova-Bogdanova A., Ivanova S., Atanasov P., Chaneva M., and Petkova V., 2023, Prevention of cardiovascular diseases, Pharmacia, 70(4): 1243-1247. https://doi.org/10.3897/pharmacia.70.e114071 Bjorklund G., Aaseth J., Chirumbolo S., Urbina M., and Uddin R., 2017, Effects of arsenic toxicity beyond epigenetic modifications. Environmental Geochemistry and Health, 40: 955-965. https://doi.org/10.1007/s10653-017-9967-9 PMid:28484874 Cha S., Kang J., Lee J., Kim J., Kim H., Yang Y., Park W., and Kim J., 2018, Impact of genetic variants on the individual potential for body fat loss, Nutrients, 10(3): 266. https://doi.org/10.3390/nu10030266 PMid:29495392 PMCid:PMC5872684 Clayton E., Evans B., Hazel J., and Rothstein M., 2019, The law of genetic privacy: applications, implications, and limitations, Journal of Law and the Biosciences, 6: 1-36. https://doi.org/10.1093/jlb/lsz007 PMid:31666963 PMCid:PMC6813935 Defesche J., Gidding S., Harada-Shiba M., Hegele R., Santos R., and Wierzbicki A., 2017, Familial hypercholesterolaemia, Nature Reviews Disease Primers, 3: 17093. https://doi.org/10.1038/nrdp.2017.93 PMid:29219151 Ference B., Robinson J., Brook R., Catapano A., Chapman M., Neff D., Voros S., Giugliano R., Smith G., Fazio S., Sabatine M., and M.P., H., 2016, Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes, The New England Journal of Medicine, 375(22): 2144-2153. https://doi.org/10.1056/NEJMoa1604304 PMid:27959767 Ginsburg G., Donahue M., and Newby L., 2005, Prospects for personalized cardiovascular medicine: the impact of genomics, Journal of the American College of Cardiology, 46(9): 1615-1627. https://doi.org/10.1016/j.jacc.2005.06.075 PMid:16256859 Heil R., Heyen N., Baumann M., Hüsing B., Bachlechner D., Schmoch U., and König H., 2021, Artificial intelligence in human genomics and biomedicine, TATuP - Zeitschrift für Technikfolgenabschätzung in Theorie und Praxis., 30(3):30-36. https://doi.org/10.14512/tatup.30.3.30 Heshmatzad K., Naderi N., Maleki M., Abbasi S., Ghasemi S., Ashrafi N., Fazelifar A., Mahdavi M., and Kalayinia S., 2023, Role of non‐coding variants in cardiovascular disease, Journal of Cellular and Molecular Medicine, 27: 1621-1636. https://doi.org/10.1111/jcmm.17762 PMid:37183561 PMCid:PMC10273088 Hopewell J., Malik R., Valdés-Márquez E., Worrall B., and Collins R., 2017, Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke, European Heart Journal, 39: 354-359. https://doi.org/10.1093/eurheartj/ehx373 PMid:29020353 PMCid:PMC5837489 Iqbal Z., Dhage S., Mohamad J., Abdel-Razik A., Donn R., Malik R., Ho J., Liu Y., Adam S., Isa B., Stefanutti C., and Soran H., 2019, Efficacy and safety of PCSK9 monoclonal antibodies, Expert Opinion on Drug Safety, 18: 1191-1201. https://doi.org/10.1080/14740338.2019.1681395 PMid:31623472 Jeong S., Kim J., Cho Y., Koh S., Kim N., and Choi J., 2020, Genetically, dietary sodium intake is causally associated with salt-sensitive hypertension risk in a community-based cohort study: a mendelian randomization approach, Current Hypertension Reports, 22: 1-10. https://doi.org/10.1007/s11906-020-01050-4 PMid:32591971 Joshi A., Rienks M., Theofilatos K., and Mayr M., 2020, Systems biology in cardiovascular disease: a multiomics approach, Nature Reviews Cardiology, 18: 313-330. https://doi.org/10.1038/s41569-020-00477-1 PMid:33340009 Katsanis S., and Katsanis N., 2013, Molecular genetic testing and the future of clinical genomics, Nature Reviews Genetics, 14: 415-426. https://doi.org/10.1038/nrg3493 PMid:23681062 PMCid:PMC4461364
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==